Biomedical Engineering Reference
In-Depth Information
7. Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD (2010) Phase-I clinical trial of IL-12
plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther
17:360-369
8. Bedikian AY, Richards J, Kharkevitch D, Atkins MB, Whitman E, Gonzalez R (2010) A
phase 2 study of high-dose allovectin-7 in patients with advanced metastatic melanoma.
Melanoma Res 20:218-226
9. Yamamoto A, Kormann M, Rosenecker J, Rudolph C (2009) Current prospects for mRNA
gene delivery. Eur J Pharm Biopharm 71:484-489
10. Kormann MS, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber-Jonat S, Huppmann
M, Mays LE, Illenyi M, Schams A, Griese M, Bittmann I, Handgretinger R, Hartl D,
Rosenecker J, Rudolph C (2011) Expression of therapeutic proteins after delivery of chemi-
cally modified mRNA in mice. Nat Biotechnol 29:154-157
11. Yin H, Lu Q, Wood M (2008) Effective exon skipping and restoration of dystrophin
expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther
16:38-45
12. Krutzfeldt J, Rajewsky N, Braich R, Rajeev K, Tuschl T, Manoharan M, Stoffel M (2005)
Silencing of microRNAs in vivo with 'antagomirs'. Nature 438:685-689
13. Fabani MM, Gait MJ (2008) miR-122 targeting with LNA/2'-O-methyl oligonucleotide
mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 14:336-346
14. Crooke ST (2004) Progress in antisense technology. Annu Rev Med 55:61-95
15. Veedu RN, Wengel J (2009) Locked nucleic acid as a novel class of therapeutic agents. RNA
Biol 6:321-323
16. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of
21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature
411:494-498
17. Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, prospects and challenges. Adv
Drug Deliv Rev 59:75-86
18. Meyer M, Wagner E (2006) Recent developments in the application of plasmid DNA-based
vectors and small interfering RNA therapeutics for cancer. Hum Gene Ther 17:1062-1076
19. Aigner A (2006) Gene silencing through RNA interference (RNAi) in vivo: strategies based
on the direct application of siRNAs. J Biotechnol 124:12-25
20. Gao K, Huang L (2009) Nonviral methods for siRNA delivery. Mol Pharmaceutics
6:651-658
21. Behlke MA (2008) Chemical modification of siRNAs for in vivo use. Oligonucleotides
18:305-319
22. Li L, Shen Y (2009) Overcoming obstacles to develop effective and safe siRNA therapeutics.
Expert Opin Biol Ther 9:609-619
23. Frohlich T, Wagner E (2010) Peptide- and polymer-based delivery of therapeutic RNA. Soft
Matter 6:226-234
24. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW,
Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT (2009)
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.
Cell 137:1005-1017
25. Aigner A, Fischer D, Merdan T, Brus C, Kissel T, Czubayko F (2002) Delivery of unmodified
bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-
regulates gene expression. Gene Ther 9:1700-1707
26. Tomita N, Azuma H, Kaneda Y, Ogihara T, Morishita R (2004) Application of decoy
oligodeoxynucleotides-based approach to renal diseases. Curr Drug Targets 5:717-733
27. Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D, Sullenger BA (2002) RNA
aptamers as reversible antagonists of coagulation factor IXa. Nature 419:90-94
28. Ulrich H, Trujillo CA, Nery AA, Alves JM, Majumder P, Resende RR, Martins AH (2006)
DNA and RNA aptamers: from tools for basic research towards therapeutic applications.
Comb Chem High Throughput Screen 9:619-632
